via Rensselaer Polytechnic Institute
Heparin, a common anticoagulant, could also form the basis of a viral trap for SARS-CoV-2
In a test of antiviral effectiveness against the virus that causes COVID-19, an extract from edible seaweeds substantially outperformed remdesivir, the current standard antiviral used to combat the disease. Heparin, a common blood thinner, and a heparin variant stripped of its anticoagulant properties, performed on par with remdesivir in inhibiting SARS-CoV-2 infection in mammalian cells.
Published online today in Cell Discovery, the research is the latest example of a decoy strategy researchers from the Center for Biotechnology and Interdisciplinary Studies (CBIS) at Rensselear Polytechnic Institute are developing against viruses like the novel coronavirus that spawned the current global health crisis.
The spike protein on the surface of SARS-CoV-2 latches onto the ACE-2 receptor, a molecule on the surface of human cells. Once secured, the virus inserts its own genetic material into the cell, hijacking the cellular machinery to produce replica viruses. But the virus could just as easily be persuaded to lock onto a decoy molecule that offers a similar fit. The neutralized virus would be trapped and eventually degrade naturally.
Previous research has shown this decoy technique works in trapping other viruses, including dengue, Zika, and influenza A.
“We’re learning how to block viral infection, and that is knowledge we are going to need if we want to rapidly confront pandemics,” said Jonathan Dordick, the lead researcher and a professor of chemical and biological engineering at Rensselaer Polytechnic Institute. “The reality is that we don’t have great antivirals. To protect ourselves against future pandemics, we are going to need an arsenal of approaches that we can quickly adapt to emerging viruses.”
The Cell Discovery paper tests antiviral activity in three variants of heparin (heparin, trisulfated heparin, and a non-anticoagulant low molecular weight heparin) and two fucoidans (RPI-27 and RPI-28) extracted from seaweed. All five compounds are long chains of sugar molecules known as sulfated polysaccharides, a structural conformation that the results of a binding study published earlier this month in Antiviral Research suggested as an effective decoy.
The researchers performed a dose response study known as an EC50 — shorthand for the effective concentration of the compound that inhibits 50% of viral infectivity — with each of the five compounds on mammalian cells. For the results of an EC50, which are given in a molar concentration, a lower value signals a more potent compound.
RPI-27 yielded an EC50 value of approximately 83 nanomolar, while a similar previously published and independent in vitro test of remdesivir on the same mammalian cells yielded an EC50 of 770 nanomolar. Heparin yielded an EC50 of 2.1 micromolar, or about one-third as active as remdesivir, and a non-anticoagulant analog of heparin yielded an EC50 of 5.0 micromolar, about one-fifth as active as remdesivir.
A separate test found no cellular toxicity in any of the compounds, even at the highest concentrations tested.
“What interests us is a new way of getting at infection,” said Robert Linhardt, a Rensselaer professor of chemistry and chemical biology who is collaborating with Dordick to develop the decoy strategy. “The current thinking is that the COVID-19 infection starts in the nose, and either of these substances could be the basis for a nasal spray. If you could simply treat the infection early, or even treat before you have the infection, you would have a way of blocking it before it enters the body.”
Dordick added that compounds from seaweed “could serve as a basis for an oral delivery approach to address potential gastrointestinal infection.”
In studying SARS-CoV-2 sequencing data, Dordick and Linhardt recognized several motifs on the structure of the spike protein that promised a fit compatible with heparin, a result borne out in the binding study. The spike protein is heavily encrusted in glycans, an adaptation that protects it from human enzymes which could degrade it, and prepares it to bind with a specific receptor on the cell surface.
“It’s a very complicated mechanism that we quite frankly don’t know all the details about, but we’re getting more information,” said Dordick. “One thing that’s become clear with this study is that the larger the molecule, the better the fit. The more successful compounds are the larger sulfated polysaccharides that offer a greater number of sites on the molecules to trap the virus.”
Molecular modeling based on the binding study revealed sites on the spike protein where the heparin was able to interact, raising the prospects for similar sulfated polysaccharides.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Coronavirus decoy strategy
- Tom Claycomb: Patterning your turkey shotgunon March 2, 2021 at 11:20 pm
In my Turkey Seminars I teach that calling is about 20% of the puzzle. You have to also learn strategy, camo, decoys and many other details if you want to be successful. Calling is actually only a ...
- No. 17 Oklahoma State completes sweep of No. 16 Oklahomaon March 1, 2021 at 8:43 pm
Cunningham had 40 points in Saturday’s 94-90 overtime win at Oklahoma. This time, the 6-foot-8 point guard was a decoy much of the night but finished strong. “Cade just takes the pressure off ...
- These civilians hunt child predators. Expert warns they're 'playing with fire.'on February 25, 2021 at 3:32 am
the woman asked. “Basically, I brought you out here ‘cause we know who you are, I’m definitely not 14, you’ve definitely been talking to a decoy,” the woman said while walking with Boyer ...
- Derrick Lewis KO's Curtis Blaydes in biggest UFC main event upset in 5 yearson February 20, 2021 at 8:53 pm
Curtis Blaydes made no apologies about his strategy coming into a huge heavyweight ... but Blaydes tested positive for COVID-19, and the contest was pulled one day prior to the event before ...
- Direct cloning method aims to accelerate large-scale discovery of novel natural productson February 19, 2021 at 4:00 pm
Researchers at University of Illinois Urbana-Champaign previously demonstrated a technique using transcription factor decoys to activate ... an example on how this strategy can be applied for ...
Go deeper with Google Headlines on:
Coronavirus decoy strategy
Go deeper with Bing News on:
- Unfractionated Heparin Market by Production, Consumption Professional Analysis, Business Prospect, Regional Growth and Forecast to 2025on March 6, 2021 at 4:09 am
The Global " Unfractionated Heparin Market "Report provides sizing and growth opportunities for the forecast period 2021-2025. Provides comprehensive insights on the latest industry trends, forecast, ...
- COVID-19: Antiplatelet Agents May Reduce Thrombotic Riskon March 4, 2021 at 12:19 pm
Severe COVID-19 patients have sustained platelet activation, likely contributing to thrombotic issues seen with the infection. Antiplatelet therapy such as aspirin may be of benefit, researchers say.
- Insights on the Global Heparin Market 2020-2024: COVID-19 Industry Analysis, Market Trends, Market Growth, Opportunities and Forecast 2024 - Technavioon March 3, 2021 at 3:44 pm
Based on the product, the subcutaneous injection segment is expected to witness lucrative growth during the forecast period. Heparin Market: Geographic Landscape. By geography, Eu ...
- Weight-based Heparin Protocol using Antifactor Xa Monitoringon March 1, 2021 at 4:01 pm
Purpose. The performance of a weight-based dosing protocol for unfractionated heparin (UFH) infusions using antifactor Xa monitoring was evaluated. Methods. The first 50 patients to receive a UFH ...
- Global Bovine Heparin Market Share 2021 Top Manufacturers, Size, Market Analysis, Growth Opportunities, Trends, Forecast to 2026on February 23, 2021 at 1:22 am
The Bovine Heparin Market forecast 2025 research report provides a basic overview of the industry including market analysis, definitions, classifications, applications, and Bovine Heparin industry ...